CO2019007670A2 - Un derivado de oxazina base libre en forma cristalina - Google Patents
Un derivado de oxazina base libre en forma cristalinaInfo
- Publication number
- CO2019007670A2 CO2019007670A2 CONC2019/0007670A CO2019007670A CO2019007670A2 CO 2019007670 A2 CO2019007670 A2 CO 2019007670A2 CO 2019007670 A CO2019007670 A CO 2019007670A CO 2019007670 A2 CO2019007670 A2 CO 2019007670A2
- Authority
- CO
- Colombia
- Prior art keywords
- crystalline form
- compound
- free base
- oxazine derivative
- solid
- Prior art date
Links
- 239000012458 free base Substances 0.000 title 1
- 150000004893 oxazines Chemical class 0.000 title 1
- 229940125904 compound 1 Drugs 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a una forma sólida, a decir, la Forma A cristalina, del Compuesto 1, y divulga el proceso para la preparación de dicha forma sólida de Compuesto 1. Además se divulgan otras formas sólidas del Compuesto 1, que incluyen su forma de hidrato y amorfa. La presente invención además se refiere a una composición farmacéutica que comprende la Forma A cristalina de Compuesto 1, y métodos de uso de dicha forma y composición farmacéutica en el tratamiento o la prevención de la enfermedad de Alzheimer o angiopatía amiloide cerebral.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17152481 | 2017-01-20 | ||
PCT/IB2018/050314 WO2018134761A1 (en) | 2017-01-20 | 2018-01-18 | A free base oxazine derivative in crystalline form |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019007670A2 true CO2019007670A2 (es) | 2019-07-31 |
Family
ID=57890668
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0007671A CO2019007671A2 (es) | 2017-01-20 | 2019-07-17 | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer |
CONC2019/0007670A CO2019007670A2 (es) | 2017-01-20 | 2019-07-17 | Un derivado de oxazina base libre en forma cristalina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0007671A CO2019007671A2 (es) | 2017-01-20 | 2019-07-17 | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer |
Country Status (21)
Country | Link |
---|---|
US (2) | US20200048237A1 (es) |
EP (2) | EP3571195A1 (es) |
JP (2) | JP2020505363A (es) |
KR (1) | KR20190126291A (es) |
CN (1) | CN110167535A (es) |
AR (1) | AR110758A1 (es) |
AU (3) | AU2018209442A1 (es) |
BR (2) | BR112019014825A2 (es) |
CA (2) | CA3048346A1 (es) |
CL (1) | CL2019002020A1 (es) |
CO (2) | CO2019007671A2 (es) |
CR (1) | CR20190333A (es) |
IL (2) | IL267640A (es) |
JO (2) | JOP20190178A1 (es) |
MX (2) | MX2019008603A (es) |
PE (2) | PE20191250A1 (es) |
RU (1) | RU2019126022A (es) |
SG (2) | SG11201905116PA (es) |
TW (1) | TW201828943A (es) |
UY (1) | UY37572A (es) |
WO (2) | WO2018134760A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019142111A1 (en) * | 2018-01-18 | 2019-07-25 | Novartis Ag | Salt forms of an oxazine derivative bace inhibitor |
CN112661667B (zh) * | 2020-12-28 | 2023-02-03 | 浦拉司科技(上海)有限责任公司 | 一种三氟乙脒的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP3807A (en) | 2011-01-13 | 2016-09-30 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
-
2017
- 2017-06-16 JO JOP/2019/0178A patent/JOP20190178A1/ar unknown
- 2017-06-16 JO JOP/2019/0180A patent/JOP20190180A1/ar unknown
-
2018
- 2018-01-18 CR CR20190333A patent/CR20190333A/es unknown
- 2018-01-18 EP EP18701600.1A patent/EP3571195A1/en not_active Withdrawn
- 2018-01-18 CA CA3048346A patent/CA3048346A1/en not_active Abandoned
- 2018-01-18 WO PCT/IB2018/050312 patent/WO2018134760A1/en unknown
- 2018-01-18 US US16/478,736 patent/US20200048237A1/en not_active Abandoned
- 2018-01-18 TW TW107101806A patent/TW201828943A/zh unknown
- 2018-01-18 SG SG11201905116PA patent/SG11201905116PA/en unknown
- 2018-01-18 JP JP2019539215A patent/JP2020505363A/ja active Pending
- 2018-01-18 KR KR1020197020514A patent/KR20190126291A/ko not_active Application Discontinuation
- 2018-01-18 AU AU2018209442A patent/AU2018209442A1/en not_active Abandoned
- 2018-01-18 EP EP18701232.3A patent/EP3570820A1/en not_active Withdrawn
- 2018-01-18 AU AU2018208870A patent/AU2018208870A1/en not_active Abandoned
- 2018-01-18 PE PE2019001437A patent/PE20191250A1/es unknown
- 2018-01-18 BR BR112019014825-6A patent/BR112019014825A2/pt not_active Application Discontinuation
- 2018-01-18 JP JP2019539254A patent/JP2020505367A/ja active Pending
- 2018-01-18 CA CA3046304A patent/CA3046304A1/en not_active Abandoned
- 2018-01-18 MX MX2019008603A patent/MX2019008603A/es unknown
- 2018-01-18 WO PCT/IB2018/050314 patent/WO2018134761A1/en unknown
- 2018-01-18 CN CN201880006121.3A patent/CN110167535A/zh active Pending
- 2018-01-18 MX MX2019008601A patent/MX2019008601A/es unknown
- 2018-01-18 RU RU2019126022A patent/RU2019126022A/ru not_active Application Discontinuation
- 2018-01-18 US US16/478,704 patent/US20190388428A1/en not_active Abandoned
- 2018-01-18 SG SG11201905528XA patent/SG11201905528XA/en unknown
- 2018-01-18 BR BR112019014234-7A patent/BR112019014234A2/pt not_active IP Right Cessation
- 2018-01-18 PE PE2019001432A patent/PE20191346A1/es unknown
- 2018-01-19 AR ARP180100124A patent/AR110758A1/es unknown
- 2018-01-19 UY UY0001037572A patent/UY37572A/es not_active Application Discontinuation
-
2019
- 2019-06-25 IL IL267640A patent/IL267640A/en unknown
- 2019-07-17 CO CONC2019/0007671A patent/CO2019007671A2/es unknown
- 2019-07-17 IL IL268131A patent/IL268131A/en unknown
- 2019-07-17 CO CONC2019/0007670A patent/CO2019007670A2/es unknown
- 2019-07-18 CL CL2019002020A patent/CL2019002020A1/es unknown
-
2020
- 2020-12-15 AU AU2020289738A patent/AU2020289738A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
CL2019001066A1 (es) | Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854) | |
CL2019003610A1 (es) | Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477). | |
PH12017502001A1 (en) | Amido-substituted cyclohexane derivatives | |
CR20190212A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
CU20170077A7 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende | |
PH12016501581A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
UY35916A (es) | Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio | |
GT201300254A (es) | Triazolopiridinas | |
UY37460A (es) | 1,2,4-triazolonas con anelación en 4 y 5 | |
BR112016011065A8 (pt) | composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia | |
MX2016002241A (es) | Alcoholes de alquinilo y metodos de uso. | |
CL2017001574A1 (es) | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabólicos relacionados | |
EA201791802A1 (ru) | СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС | |
BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
MX2016003823A (es) | Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma. | |
CO2021000932A2 (es) | Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma | |
UY36677A (es) | Compuestos tricíclicos como agentes antineoplásicos | |
CO2019007670A2 (es) | Un derivado de oxazina base libre en forma cristalina | |
UY36347A (es) | Compuestos y su uso como inhibidores de bace | |
MX2016008968A (es) | Compuestos organicos. | |
PH12020500045A1 (en) | Novel composition of enzalutamide oral dosage form and method of manufacturing thereof | |
ES2721922T3 (es) | Tratamiento o prevención del daño neuronal no inflamatorio por traumatismo cerebral e ictus utilizando mentol, linalool y/o icilina | |
BR112019005297A2 (pt) | composto, composição farmacêutica, e, métodos para tratamento de hipertensão ou pré-hipertensão e de fibrose. |